Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 2—February 2022
Dispatch

SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, March–June 2021

Taufiqur Rahman Bhuiyan1, Juan Dent Hulse1, Sonia T. Hegde1, Marjahan Akhtar, Taufiqul Islam, Zahid Hasan Khan, Ishtiakul Islam Khan, Shakeel Ahmed, Mamunur Rashid, Rumana Rashid, Emily S. Gurley, Tahmina Shirin, Ashraful Islam Khan, Andrew S. Azman2Comments to Author , and Firdausi Qadri2
Author affiliations: icddr,b, Dhaka, Bangladesh (T.R. Bhuiyan, M. Akhtar, T. Islam, Z.H. Khan, I.I. Khan, A.I. Khan, F. Qadri); Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (J.Dent. Hulse, S.T. Hegde, E.S. Gurley, A.S. Azman); Bangladesh Institute of Tropical and Infectious Diseases, Chattogram, Bangladesh (S. Ahmed, M. Rashid, R. Rashid); Institute of Epidemiology, Disease Control and Research, Dhaka (T. Shirin); Institute of Global Health, University of Geneva, Geneva, Switzerland (A.S. Azman)

Main Article

Table

Overview of SARS-CoV-2 seropositivity, seroprevalence and relative risk seropositivity in Sitakunda subdistrict, Chattogram district, Bangladesh*

Variable Observations, no. Positive, no. (%) Negative, no. (%) Adjusted seroprevalence, % (95% CrI) Adjusted relative risk, % (95% CrI)
Age, y
1–4 90 37 (41.1) 53 (58.9) 47.1 (37.0–57.3) 0.66 (0.51–0.81)
5–9 174 71 (40.8) 103 (59.2) 45.0 (37.1–52.9) 0.63 (0.51–0.74)
10–14 258 140 (54.3) 118 (45.7) 58.8 (52.0–65.3) 0.83 (0.73–0.94)
15–24 482 305 (63.3) 177 (36.7) 67.2 (61.7–72.6) 0.96 (0.88–1.05)
25–34 381 258 (67.7) 123 (32.3) 69.7 (64.5–75.0) Referent
35–44 325 225 (69.2) 100 (30.8) 74.0 (68.3–79.5) 1.07 (0.97–1.17)
45–54 250 180 (72.0) 70 (28.0) 73.8 (67.2–80.3) 1.06 (0.96–1.17)
55–64 208 132 (63.5) 76 (36.5) 69.0 (62.1–75.8) 0.99 (0.88–1.10)
>65
 139
 95 (68.3)
 44 (31.7)
 73.6 (65.8–81.1)
 1.06 (0.94–1.19)
Sex
M 1,072 690 (64.4) 382 (35.6) 66.7 (62.2–71.3) 1.07 (1.02–1.13)
F
 1,235
 753 (61.0)
 482 (39.0)
 61.3 (56.9–65.6)
 Referent
Overall
 2,307
 1,443 (62.5)
 864 (37.5)
 64.1 (60.0–68.1)
 NA
*Adjusted estimates account for sex, age, household clustering, and test performance among all vaccinated and unvaccinated participants. CrI, credible interval; NA, not applicable.

Main Article

1These first authors contributed equally to this article.

2These senior authors contributed equally to this article.

Page created: December 17, 2021
Page updated: January 22, 2022
Page reviewed: January 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external